Find a Collaborator

A/Prof Alfredo FRANCO-OBREGON

Cancer Stem Cells
I approach tissue engineering, regeneration and development from a biophysical perspective, as an alternative to conventional pharmacological interventions. I am particularly interested in how mechanical and electromagnetic forces drive development and can be used to control disease. My areas of interest are skeletal muscle development, cancer and stem cell biology.

Prof KOH Liang Piu

Cancer Stem Cells
Research focuses mainly on clinical Haematopoietic Stem Cell Transplantation in particular Nonmyeloablative Stem Cell Transplant, haploidentical donor transplant, Umbilical Cord Blood Transplantation in Haematological Malignancies. He also the leading primary investigators on clinical trials on Infectious Complications in Haematological / Haematopoietic Stem Cell Transplantation Recipients, studies on Graft vs. Host Disease prevention and treatment.

Dr LIM Gkeok Stzuan, Diana

Cancer Stem Cells
Dr Diana Lim is a senior consultant pathologist and director of the Diagnostic Molecular Oncology Centre (DMOC) in National University Hospital. Her subspecialty and research interest lies in gynaecologic and molecular pathology.

Dr ONG Sek Tong, Derrick

Cancer Stem Cells
Research focus is on identifying new glioblastoma dependency in the area of cancer epigenetics as we try to develop innovative and durable GBM treatment modalities. We are also interested to understand the mechanisms that regulate non-cancerous brain stem cell function, in order to discover new ways to retard/reverse brain aging.

Dr ONG Sek Tong, Derrick

Cancer Stem Cells
Research focus is on identifying new glioblastoma dependency in the area of cancer epigenetics as we try to develop innovative and durable GBM treatment modalities. We are also interested to understand the mechanisms that regulate non-cancerous brain stem cell function, in order to discover new ways to retard/reverse brain aging.

Prof Toshio SUDA

Cancer Stem Cells
Research focus is based on the hypothesis that the bone marrow (BM) microenvironment known as the stem cells niche is essential for the maintenance of hematopoietic stem cells (HSC) quiescence in cell cycle and regulates the fate of HSCs. We aim for the regulation of stem cells by niche as niche therapy. We will dissect the niche as a functional unit of stem cell regulation and aim to expand stem cells using ex vivo artificial niches and improve the method for BM transplantation.

Prof Toshio SUDA

Cancer Stem Cells
Research focus is based on the hypothesis that the bone marrow (BM) microenvironment known as the stem cells niche is essential for the maintenance of hematopoietic stem cells (HSC) quiescence in cell cycle and regulates the fate of HSCs. We aim for the regulation of stem cells by niche as niche therapy. We will dissect the niche as a functional unit of stem cell regulation and aim to expand stem cells using ex vivo artificial niches and improve the method for BM transplantation.

A / Prof KOH Liang Piu

Cancer Stem Cells
Research focuses mainly on clinical Haematopoietic Stem Cell Transplantation in particular Nonmyeloablative Stem Cell Transplant, haploidentical donor transplant, Umbilical Cord Blood Transplantation in Haematological Malignancies. He also the leading primary investigators on clinical trials on Infectious Complications in Haematological / Haematopoietic Stem Cell Transplantation Recipients, studies on Graft vs. Host Disease prevention and treatment.

Prof Toshio SUDA

Cancer Stem Cells
Research focus is based on the hypothesis that the bone marrow (BM) microenvironment known as the stem cells niche is essential for the maintenance of hematopoietic stem cells (HSC) quiescence in cell cycle and regulates the fate of HSCs. We aim for the regulation of stem cells by niche as niche therapy. We will dissect the niche as a functional unit of stem cell regulation and aim to expand stem cells using ex vivo artificial niches and improve the method for BM transplantation.

Dr Shruti BHATT

Biomarkers/ Imaging/ Proteomics

The central focus of research is to identify treatment strategies and underlying mechanisms of therapy-resistant myeloid tumors by studying clonal evolutionary path and cell death mechanisms, particularly the mitochondrial pathway of apoptosis.

A/Prof Glenn Kunnath BONNEY

Biomarkers

A/Prof CHEE Cheng Ean

Biomarkers
Research interest is in precision oncology in colorectal, pancreas and liver cancers. I develop and conduct clinical trials with novel therapeutics and work with collaborators within and outside Singapore on translational and biomarker research in these areas. In addition, I am interested in healthcare delivery and personalizing care for our cancer survivors.

A/Prof CHEN Zhi Xiong

Biomarkers
Neuroblastoma is the leading cause of cancer death in children. Our research is to develop improved approaches for treating neuroblastoma through drug repurposing and predicting outcome in paediatric tumours through blood sample monitoring.

A/Prof CHEW Suk Peng, Valerie

Biomarkers

Research delves into deciphering the intricate immune landscape and crosstalk within the tumor microenvironment of hepatocellular carcinoma (HCC), with a keen focus on uncovering biomarkers and therapeutic avenues.

Dr CHEONG Jit Kong

Biomarkers

Research focus is on uncovering and characterising novel signalling nodes of oncogenic RAS-driven human cancers to facilitate the development of tractable therapeutic modalities.

A/Prof DENG Lih Wen

Biomarkers
Research focus is on understanding the cellular and molecular mechanism in cancer development and therapy resistance for the development of diagnostic markers and selective therapeutics against cancer resistance and metastasis.

Prof GOH Boon Cher

Biomarkers

Prof KHONG Pek-Lan

Imaging, Biomarkers

Prof LEE Soo Chin

Biomarkers
Research focuses on novel therapeutics and predictive biomarkers in breast cancer. Her team has identified a biomarker detectable in blood that predicts breast cancer recurrence, and that can be used to select patients for a novel targeted therapy.

Dr LIM Si Jing, Joline

Biomarkers

Dr LOW Jun Siong

Imaging/Proteomics

A/Prof NG Siok Bian

Biomarkers
Research focus is to identify and validate novel markers of prognostic and therapeutic importance in EBV-associated T- and NK-cell lymphomas and lymphoproliferative diseases, a group of aggressive tumours which are prevalent in Asia.

Dr NGOI Yan Li, Natalie

Biomarkers

Prof SO Bok Yan, Jimmy

Biomarkers
Research focus is to improve outcomes of patients with gastric or esophageal cancer through early detection, better understanding of their origins and novel treatment.

Dr Supriya SRIVASTAVA

Biomarkers

Pathologist with a specific focus on solid cancers, particularly gastrointestinal cancers. Research focuses on the identification and validation of biomarkers that aid in the early diagnosis of gastric cancers as well as metaplastic lesions of stomach, that are considered preneoplastic and could be targeted at an early stage thereby improving the patient outcome.

Dr TAI Yee Kit Alex

Biomarkers

Research focus is on exploring the therapeutic benefits of pulsed electromagnetic fields (PEMF) as an exercise-mimetic to enhance the vulnerability of tumor cells to chemotherapy

A/Prof TAN Shao Peng, David

Biomarkers
Research is focused on the development of biomarkers and novel therapeutic agents in gynaecological cancers; in understanding the mechanisms of treatment response and resistance in these cancers, with the aim of developing biomarkers to help stratify patients into optimal treatment strategies.

Dr TAY Kah Ping, Andy

Biomarkers/ Imaging/ Proteomics

The research focus of the Tay lab is tissue-specific drug delivery and immunotherapeutics against cancer.

Dr TAY Kai Xun, Joshua

Biomarkers

Dr Joshua Tay leads a cancer genomics laboratory, with special expertise in micro-dissected gene expression profiling from archival FFPE tissue specimens. His lab has built and patented gene expression signatures to predict patient outcomes for precision medicine.

A/Prof TAY Mei Sian, Yvonne

Biomarkers
Research focuses on understanding the role of non-coding RNAs that play a part in cancer development and exploring their potential utility as diagnostic biomarkers and targeted therapeutics for precision medicine.

A/Prof TOO Heng-Phon

Biomarkers
Research focus is on developing diagnostic tools to detect early changes in the development of cancers using small amounts of blood. We are now focusing on gene engineering of cells for treatment of cancers and other diseases.

A/Prof Balamurugan A VELLAYAPPAN

Imaging
Research focus is on the use of advanced radiation technology, such as stereotactic ablative radiotherapy (SABR/SBRT) and stereotactic radiosurgery, in the context of neuro-oncology and oligo-metastatic disease. Also interested in the use of novel imaging techniques (such as functional imaging, MR and artificial intelligence) to improve the delivery of radiation

A/Prof WANG Lingzhi

Biomarkers
Research focus is on oncology drug development/evaluation pipeline that combines cell biology, pharmacological science, and pharmacokinetic analysis. Another important area of research is the discovery of non-invasive biomarkers for early detection of cancer in high-risk populations.

Dr WONG Li Ann, Andrea

Biomarkers
Certain cancer cells develop resistance to therapy by altering their metabolic dependencies. Our research centres on the development of oxidative phosphorylation inhibitors as a novel class of agents to overcome therapeutic resistance.

A/Prof YIP Wai Cheong, George

Biomarkers
Research interest is in understanding the biological roles of molecules called glycosaminoglycans and proteoglycans and to determine if these biomolecules can be used to predict patient outcomes and the development of new treatment.

Prof Yang ZHANG

Built on cutting-edge artificial intelligence (AI) and deep-learning techniques, we are developing new methods for protein and RNA structure prediction and protein designs. We are particularly interested in the application of the AI-based computational methods for effective cancer therapeutics, with focuses on anti-cancer peptide-drug conjugates (PDCs) and T-cell receptor (TCR)-based adoptive therapy.

Dr ZHOU Jianbiao

Biomarkers

Research focus is on the drug resistance mechanisms and aggressive phenotypes in hematologic malignancies, as well as the development predictive markers, novel therapeutic targets.

A/Prof YIP Wai Cheong, George

Biomarkers
Research interest is in understanding the biological roles of molecules called glycosaminoglycans and proteoglycans and to determine if these biomolecules can be used to predict patient outcomes and the development of new treatment.

Prof Yang ZHANG

Built on cutting-edge artificial intelligence (AI) and deep-learning techniques, we are developing new methods for protein and RNA structure prediction and protein designs. We are particularly interested in the application of the AI-based computational methods for effective cancer therapeutics, with focuses on anti-cancer peptide-drug conjugates (PDCs) and T-cell receptor (TCR)-based adoptive therapy.

Dr Shruti BHATT

Cell Signaling

The central focus of research is to identify treatment strategies and underlying mechanisms of therapy-resistant myeloid tumors by studying clonal evolutionary path and cell death mechanisms, particularly the mitochondrial pathway of apoptosis.

Prof Dario CAMPANA

Cell Signaling
Research focus is on the development of innovative technologies to treat cancer with immune cells, and their translation into first-in human clinical trials.

Dr CHEOK Chit Fang

Cell Signaling
Research focus is on understanding the cellular and molecular mechanism in cancer development and therapy resistance for the development of diagnostic markers and selective therapeutics against cancer resistance and metastasis.

Dr CHEONG Jit Kong

Cell Signaling

Research focus is on uncovering and characterising novel signalling nodes of oncogenic RAS-driven human cancers to facilitate the development of tractable therapeutic modalities.

Dr Alan Prem KUMAR

Cell Signaling
Research focus is on uncovering new cues that drive the spread of cancer and develop target-based precision therapies to prevent metastasis in several types of female reproductive cancers.

Dr LOW Jun Siong

Cell Signaling

T and B cells are components of the immune system that are essential in fighting against infection-causing “foreign” pathogens, but are also involved in disease settings like cancer and autoimmunity where they can attack “self”. Our lab aims to understand the complex biology of T and B cells at the interplay of infection and cancer, by focusing on their phenotypic and functional profiles, antigen specificities and receptor repertoires. Our long-term goal is to develop rational and effective immune-based therapies to leverage on the immune system to fight cancer. 

A/Prof Gautam SETHI

Cell Signaling

Research focus is to elucidate the mechanism(s) of activation of oncogenic transcription factors and identification of novel inhibitors of these proteins for cancer prevention as well as therapy.

Dr TAI Yee Kit

Cell Signaling

Research focus is on exploring the therapeutic benefits of pulsed electromagnetic fields (PEMF) as an exercise-mimetic to enhance the vulnerability of tumor cells to chemotherapy.

Dr ZHOU Jianbiao

Cell Signaling

Research focus is on the drug resistance mechanisms and aggressive phenotypes in hematologic malignancies, as well as the development predictive markers, novel therapeutic targets.

A/Prof CHEN Leilei, Polly

RNA Biology
Research focus is on identifying how the harmful changes that occur in RNA molecules trigger a cell to develop into cancer which can eventually lead to the unsatisfactory treatment outcomes for patients with cancers. The long-term goal of Dr Chen’s team is to develop novel cancer therapies targeting these cancer-associated RNA changes.

Dr CHEONG Jit Kong

RNA Biology

Research focus is on uncovering and characterising novel signalling nodes of oncogenic RAS-driven human cancers to facilitate the development of tractable therapeutic modalities.

Dr ENG Wee Ling, Gracie

RNA Biology

Research interest focuses on the role of miRNAs as a biomarker for diagnosis and prognosis, and as a potential therapeutic biomolecule in a variety of diseases.

Dr TAY Kah Ping, Andy

RNA Biology

The research focus of the Tay lab is tissue-specific drug delivery and immunotherapeutics against cancer.

A/Prof TAY Mei Sian, Yvonne

RNA Biology
Research focuses on understanding the role of non-coding RNAs that play a part in cancer development and exploring their potential utility as diagnostic biomarkers and targeted therapeutics for precision medicine.

A/Prof TOO Heng-Phon

RNA Biology
Research focus is on developing diagnostic tools to detect early changes in the development of cancers using small amounts of blood. We are now focusing on gene engineering of cells for treatment of cancers and other diseases.

Prof Yang ZHANG

RNA Biology

Built on cutting-edge artificial intelligence (AI) and deep-learning techniques, we are developing new methods for protein and RNA structure prediction and protein designs. We are particularly interested in the application of the AI-based computational methods for effective cancer therapeutics, with focuses on anti-cancer peptide-drug conjugates (PDCs) and T-cell receptor (TCR)-based adoptive therapy.

A/Prof TAY Mei Sian, Yvonne

RNA Biology
Research focuses on understanding the role of non-coding RNAs that play a part in cancer development and exploring their potential utility as diagnostic biomarkers and targeted therapeutics for precision medicine.

A/Prof TOO Heng-Phon

RNA Biology
Research focus is on developing diagnostic tools to detect early changes in the development of cancers using small amounts of blood. We are now focusing on gene engineering of cells for treatment of cancers and other diseases.

Dr Shruti BHATT

Genomics/ Epigenetics/ Transcriptional regulation

The central focus of research is to identify treatment strategies and underlying mechanisms of therapy-resistant myeloid tumors by studying clonal evolutionary path and cell death mechanisms, particularly the mitochondrial pathway of apoptosis.

A/Prof CHEN Ee Sin

Epigenetics

A/Prof CHEN Leilei, Polly

Epigenetics
Research focus is on identifying how the harmful changes that occur in RNA molecules trigger a cell to develop into cancer which can eventually lead to the unsatisfactory treatment outcomes for patients with cancers. The long-term goal of Dr Chen’s team is to develop novel cancer therapies targeting these cancer-associated RNA changes.

Dr CHEONG Jit Kong

Genomics

Research focus is on uncovering and characterising novel signalling nodes of oncogenic RAS-driven human cancers to facilitate the development of tractable therapeutic modalities.

A/Prof CHEW Suk Peng, Valerie

Genomics/ Epigenetics/ Transcriptional regulation

Research delves into deciphering the intricate immune landscape and crosstalk within the tumor microenvironment of hepatocellular carcinoma (HCC), with a keen focus on uncovering biomarkers and therapeutic avenues.

Prof CHNG Wee Joo

Genomics
Research focus is on blood cancers to understand how the disease develops and find better ways to treat them.

A/Prof DENG Lih Wen

Genomics
Research focus is on understanding the cellular and molecular mechanism in cancer development and therapy resistance for the development of diagnostic markers and selective therapeutics against cancer resistance and metastasis.

Dr Dennis KAPPEI

Transcriptional regulation
Research focus is on DNA-protein interactions and changes in chromatin composition by quantitative mass spectrometry. In particular, focus is on telomeres and their impact on genome stability as well as on related transcriptional regulation at (mutated) promoters or enhancers.

A/Prof LEE Kwan Min, Victor

Epigenetics/ Genomics
Research passion is in the field of bone and soft tissue tumours for both paediatric and adult patients. My general interest involves investigating the clinical, pathological characteristics and biology of these tumours. From there, I hope to identify and characterize the oncogenic mechanisms, test or develop biomarkers for diagnostic, prognostic and therapeutic applications.

Dr Shawn LEE Hsien Ren

Genomics

Research interests lies in pharmacogenomics and immunogenomics in childhood leukemia; translating these precision modalities into greater personalised therapy to reduce toxicities and improve outcomes in acute leukemias.

Dr LEONG Sai Mun

Genomics

Adapting the use of evolutionary game theory, sociobiology and mathematical modelling on top of conventional molecular and cellular oncology, my team and I aim to unveil the nature of social relationships amongst cancer cells and study how perturbation in these relationships may affect outcome of cancer treatment.

A/Prof Norbert LEHMING

Genomics
Research focuses on using yeast as a tool to identify novel protein partners for human and yeast proteins that are relevant for important biological processes like the expression of genes and the repair of damaged DNA.

A/Prof LIM Gkeok Stzuan, Diana

Epigentics
Dr Diana Lim is a senior consultant pathologist and director of the Diagnostic Molecular Oncology Centre (DMOC) in National University Hospital. Her subspecialty and research interest lies in gynaecologic and molecular pathology.

Prof Shazib PERVAIZ

Genomics

Dr Jason PITT

Genomics
Research focus is on generating and applying computational methods to understand the causes and consequences of genomic instability in cancer. Additionally, we develop innovative genomic data democratization platforms to enhance scientific discovery as well as precision oncology.

Dr Sriram SRIDHARAN

Genomics

Research focus is to study how DNA replication is a source of genome instability. I aim to understand why and how the (epi)genome acts as an impediment to faithful DNA replication. 

A/Prof TAM Wai Leong

Transcriptional regulation
Research focus is on harnessing functional genomics to understand dysregulation in cellular metabolism and cell state perturbations for revealing principles of cancer stemness, resistance and metastasis.

Dr TAY Kai Xun, Joshua

Genomics

Dr Joshua Tay leads a cancer genomics laboratory, with special expertise in micro-dissected gene expression profiling from archival FFPE tissue specimens. His lab has built and patented gene expression signatures to predict patient outcomes for precision medicine.

Dr TEE Wee Wei

Epigentics
Research interest is to study how cancer cells undergo epigenetic reprogramming to induce phenotypic plasticity, contributing to cancer cell metastasis that escape from therapeutic pressures and the emergence of drug-tolerant persistent state.

Prof Daniel TENEN

Transcriptional regulation/ Epigenetics
Research focus is on gene regulation in normal cells and cancer, mainly in leukaemia, lung cancer, and liver cancer. Current interests are transcription factors, epigenetics, and weird long noncoding RNAs in these processes, as well as targeting the oncofoetal protein SALL4.

Prof Ashok VENKITARAMAN

Genomics
Research focus is on deciphering the mechanisms underlying cancer susceptibility to intercept cancer evolution.

A/Prof YAP Suen Mei, Celestial

Genomics
The expertise and commitment of my research extend expansively across human diseases and human biology including cancer. In addition, we have special interests in the roles of the cytoskeleton in cancer. My research group has developed both in vitro techniques incorporating molecular and bioinformatics technology, as well as in vivo approaches to investigating human diseases such as cancers.

A/Prof YEOH Eng Juh, Allen

Genomics
Research focus is on improving Acute Lymphoblastic Leukaemia treatment in children and adults by better prediction of each patient’s risk of relapse using highly sensitive biomarkers like RNA-Seq and MRD measurements. A/Prof Yeoh works on immune cell therapy especially CAR-T cell therapy for leukaemia with Prof Dario Campana in NUSMed.

Dr YONG Wei Peng

Epigenetics

Prof Yang ZHANG

Genomics / Epigenetics / Transcriptional regulation

Built on cutting-edge artificial intelligence (AI) and deep-learning techniques, we are developing new methods for protein and RNA structure prediction and protein designs. We are particularly interested in the application of the AI-based computational methods for effective cancer therapeutics, with focuses on anti-cancer peptide-drug conjugates (PDCs) and T-cell receptor (TCR)-based adoptive therapy.

Dr ZHOU Jianbiao

Genomics

Research focus is on the drug resistance mechanisms and aggressive phenotypes in hematologic malignancies, as well as the development predictive markers, novel therapeutic targets.

Dr ZHOU Jianbiao

Genomics

Research focus is on the drug resistance mechanisms and aggressive phenotypes in hematologic malignancies, as well as the development predictive markers, novel therapeutic targets.